ERBB3 and melanoma: Interestingly, treatment of SKMEL28-YAP5SA cells with high doses of UFH or the LMWH nadroparin efficiently suppressed ERBB3 and AXL activity, comparably to loss of SLC35B2 (Fig. 6g), further supporting HS dependency of ERBB3 and AXL signaling in melanoma cells.